Browse the corpus

Intracerebral hemorrhage (ICH) is a life-threatening subtype of stroke characterized by bleeding into the brain parenchyma, resulting in primary mechanical injury and secondary inflammatory damage. Representing 10% to 15% of all strokes, non-traumatic ICH carries high morbidity and mortality, particularly when associated with intraventricular extension. This course outlines the underlying etiologies of ICH, with chronic hypertension and cerebral amyloid angiopathy accounting for most primary cases, while vascular malformations, anticoagulation, neoplasms, and hemorrhagic transformation of ischemic stroke contribute to secondary causes. The need for rapid diagnosis with non-contrast computed tomography (CT) is also discussed, as hematoma expansion within the first 24 hours is common and strongly predicts outcome. This activity reviews current evidence regarding risk stratification, imaging interpretation, acute stabilization, and medical and surgical management strategies, focusing on airway stabilization, blood pressure control, reversal of coagulopathy, prevention of secondary brain injury, and selective surgical or minimally invasive intervention. Participants will strengthen their ability to recognize early neurological deterioration, mitigate hematoma expansion, manage complications, eg, hydrocephalus and seizures, and apply guideline-directed blood pressure and anticoagulation reversal protocols. This activity for healthcare professionals is designed to enhance the learner's competence in identifying ICH, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition. Objectives: Identify the pathophysiologic mechanisms underlying primary and secondary intracerebral hemorrhagic stroke. Differentiate primary from secondary intracerebral hemorrhage based on diagnostic findings. Select appropriate interventions based on hemorrhage characteristics. Collaborate with interprofessional teams to improve care coordination and outcomes in patients with intracerebral hemorrhagic stroke. Access free multiple choice questions on this topic.

Intracerebral hemorrhage (ICH) is a subtype of intra-axial intracranial hemorrhage in which the bleed occurs within the interstitial space, where neurons and microglial cells reside. Please see StatPearls' companion resource, "Intracranial Hemorrhage Overview," for further information regarding all types of intracranial hemorrhage. Non-traumatic, spontaneous ICH comprises 10% to 15% of all strokes and is associated with high morbidity and mortality, almost 50% when associated with intraventricular hemorrhage, within the first month.[1][2] Most of these cases represent spontaneous subarachnoid hemorrhages due to aneurysmal rupture. Please see StatPearls' companion resource, "Subarachnoid Hemorrhage," for further information. Although the majority of strokes occur in individuals older than 50, approximately 10-15% of strokes occur in patients aged 18 to 50 years.[3] Notably, half of strokes in children are hemorrhagic.[4] ICH risk factors include chronic hypertension, amyloid angiopathy, anticoagulation (medication), tumors, trauma, and vascular malformations. The resultant brain injury is often classified as primary, which is the initial damage to the parenchyma by the blood clot, or secondary (damage caused by complications from intracranial blood). When blood accumulation adversely affects an eloquent area of the brain, eg, a sudden deficit in speech or sensorimotor function, it may be referred to as an intraparenchymal hemorrhage. In clinical practice, the 2 terms are often interchangeable and used synonymously. In an acute setting, computed tomography (CT) has greater sensitivity than a brain MRI for detecting hemorrhages greater than 2 mm, but MRI allows further characterization of the hemorrhagic lesion. Management of ICH ranges from medical therapy to open surgery to actively evacuate the hematoma, with ongoing studies evaluating minimally invasive therapies to improve prognosis.

Non-traumatic ICH is classified as primary or secondary. Primary hemorrhages account for 85% of all ICH cases and most commonly result from chronic hypertension or cerebral amyloid angiopathy.[1][2] Secondary hemorrhage arises from identifiable causes, including bleeding diathesis that may be iatrogenic, congenital, or acquired secondary to anticoagulant or antiplatelet therapy, vascular malformations, particularly in children and young adults, neoplasms, hemorrhagic conversion of an ischemic stroke, and drug abuse.[3][4][5] Primary Intracerebral Hemorrhage Primary ICH remains a diagnosis of exclusion, established when no structural or pathological cause can be identified and supported by a history of chronic hypertension, advanced age, and characteristic clot location. Chronic arterial hypertension promotes lipohyalinosis and degenerative changes in penetrating arterioles, leading to the formation of Charcot-Bouchard aneurysms within small vessels supplying deep cerebral structures.[6] More than 60% of primary bleeds are associated with hypertension, and hematomas most frequently involve the posterior fossa, pons, basal ganglia, and thalamus.[6] Lobar hemorrhages in older patients commonly reflect amyloid angiopathy, a degenerative condition associated with apolipoprotein E gene alleles that promote amyloid deposition within vessel walls.[7] Secondary Intracerebral Hemorrhage Secondary ICH results from underlying structural pathology, eg, vascular anomalies or malignant tissue.[5] Vascular lesions include arteriovenous malformations, cavernous malformations, cerebral aneurysms, and arteriovenous fistulae, which frequently account for ICH in younger, otherwise healthy individuals. Intracranial hematomas may also develop secondary to primary or metastatic tumors or following hemorrhagic transformation of a recent ischemic infarct.[7][5] Congenital and acquired bleeding diatheses contribute substantially to ICH incidence, which is increasingly associated with the widespread use of anticoagulants, eg, warfarin and direct oral anticoagulants, and antiplatelet agents, including aspirin, clopidogrel, and ticagrelor.[2] Risk Factors for Intracerebral Hemorrhage

Secondary ICH results from underlying structural pathology, eg, vascular anomalies or malignant tissue.[5] Vascular lesions include arteriovenous malformations, cavernous malformations, cerebral aneurysms, and arteriovenous fistulae, which frequently account for ICH in younger, otherwise healthy individuals. Intracranial hematomas may also develop secondary to primary or metastatic tumors or following hemorrhagic transformation of a recent ischemic infarct.[7][5] Congenital and acquired bleeding diatheses contribute substantially to ICH incidence, which is increasingly associated with the widespread use of anticoagulants, eg, warfarin and direct oral anticoagulants, and antiplatelet agents, including aspirin, clopidogrel, and ticagrelor.[2] Risk Factors for Intracerebral Hemorrhage Epidemiologic studies have identified both modifiable and non-modifiable risk factors associated with ICH. Non-modifiable factors include non-White ethnicity, advanced age, familial apolipoprotein syndromes, and male sex.[8] Modifiable contributors include alcohol misuse, nicotine exposure, and cocaine use.[2]

Stroke, both ischemic and hemorrhagic, ranks fourth among the leading causes of death in the United States, with ICH accounting for just under 20% of all cerebrovascular events nationwide.[9] In 2010, the combined global incidence of ischemic and hemorrhagic stroke reached approximately 33 million cases, corresponding to nearly 20 cases per 100,000 people annually. Hemorrhagic strokes comprised nearly one-third of total cases and accounted for over half of all stroke-related deaths.[7] Low- and middle-income regions experience ICH rates that are 2 times higher than those in more economically developed countries.[8] Despite this disparity, worldwide mortality from stroke has declined.[7] Elevated risk in less economically developed regions likely reflects limited education regarding primary prevention and reduced access to adequate medical care.[8] Higher ICH rates occur among individuals older than 55 years, males, and African and Asian populations.[10][8] Within the Japanese population, incidence rises to 55 cases per 100,000 people, a pattern attributed to higher prevalence of alcohol use and hypertension.[11]

Hemorrhages within the cerebral parenchyma are categorized into primary injury, referring to the immediate tissue damage caused by the hematoma, and secondary injury, which describes subsequent pathological changes triggered by the hemorrhage.[12] ICH, once regarded as a single-event disorder, now represents a dynamic condition characterized by multiple phases: initial extravasation of blood into the parenchyma, continued bleeding around the clot leading to expansion, and development of perihematomal swelling or edema.[2] Acute ICH causes a sudden increase in intracranial pressure, compressing and disrupting adjacent neuronal tissue, compromising local signaling pathways, and leading to focal neurological deficits.[7][12] Blood disperses through white matter, leaving small islands of intact neural tissue within and surrounding the hematoma that may remain salvageable.[8] Brainstem hematomas frequently present with decreased consciousness and cardiorespiratory distress or arrest. Hematoma expansion, defined on repeat CT as a 33-50% increase in volume, strongly predicts prognosis and functional outcome.[13] Expansion of this magnitude occurs in just under 40% of patients and correlates with increased morbidity and poorer outcomes.[7] More than 70% of ICH cases demonstrate expansion within the first 24 hours due to ongoing or recurrent bleeding. Brott et al reported hematoma enlargement within 1 hour of the initial CT scan in 26% of patients.[14] Although the mechanisms underlying growth remain incompletely defined, proposed pathways include upregulation of the inflammatory cascade, hemostatic imbalance, and increased matrix metalloproteinase expression.[13] Untreated hypertension and bleeding diathesis further elevate expansion risk.[8] Blood-brain barrier disruption, rising intracranial pressure, venous outflow obstruction, vascular engorgement, and microscopic rupture of adjacent venules and arterioles contribute to peripheral bleeding and mass effect.[13] Elevated intracranial pressure reduces cerebral perfusion pressure, promotes tissue displacement, and may precipitate herniation syndromes, compounding secondary brain injury.[7]

More than 70% of ICH cases demonstrate expansion within the first 24 hours due to ongoing or recurrent bleeding. Brott et al reported hematoma enlargement within 1 hour of the initial CT scan in 26% of patients.[14] Although the mechanisms underlying growth remain incompletely defined, proposed pathways include upregulation of the inflammatory cascade, hemostatic imbalance, and increased matrix metalloproteinase expression.[13] Untreated hypertension and bleeding diathesis further elevate expansion risk.[8] Blood-brain barrier disruption, rising intracranial pressure, venous outflow obstruction, vascular engorgement, and microscopic rupture of adjacent venules and arterioles contribute to peripheral bleeding and mass effect.[13] Elevated intracranial pressure reduces cerebral perfusion pressure, promotes tissue displacement, and may precipitate herniation syndromes, compounding secondary brain injury.[7] Secondary injury evolves as inflammatory cytokines and thrombin accumulate in the parenchyma, leading to perihematomal edema.[7][12] Edema peaks at approximately 72 hours post-ictus during the hyperacute phase.[10] Early swelling likely reflects vasogenic responses to pro-osmotic substances, including electrolytes and proteins released from the clot, followed by coagulation cascade activation and thrombin-mediated propagation.[13] After the first week, edema progression is associated with cytotoxic effects of hemoglobin degradation and reactive oxygen species formation.[13] Cerebral ischemia following hypertensive hemorrhage was previously attributed to mechanical compression by hematoma and edema under elevated pressure; however, identification of necrotic tissue surrounding ICH supports apoptosis mediated by nuclear factor-kB expression within neural cell nucleoli.[8]

A concise yet comprehensive history remains essential in acute presentations to support diagnosis, although altered sensorium and reduced consciousness frequently limit accuracy. Key historical elements in suspected ICH include symptom chronology and the precise time of ictus. Vascular events typically present suddenly and may follow high-energy activities, eg, exercise or heavy lifting, or substance use, including cocaine and alcohol. A significant smoking history contributes to vascular pathology, eg, hypertension and vasculitis, both recognized risk factors for ICH. Sudden onset of focal neurological deficit represents the most common clinical feature of ICH, with manifestation determined by hemorrhage location and associated edema. Decline in consciousness often accompanies focal deficits and requires assessment using the Glasgow Coma Scale (GCS). Additional manifestations include headache, nausea, vomiting, convulsive and nonconvulsive seizures, and elevated diastolic blood pressure exceeding 110 mm Hg.[1] Intraventricular extension of hemorrhage may produce obstructive hydrocephalus, leading to signs of increased intracranial pressure, eg, postural headache worsened by recumbency, nausea, vomiting, diplopia, confusion, and further reduction in consciousness. Initial evaluation requires prompt assessment of airway patency and ventilation adequacy, followed by circulatory evaluation and establishment of wide-bore intravenous access. A very low level of consciousness (GCS score below 8) constitutes a medical emergency and requires immediate airway protection. A comprehensive peripheral examination must follow stabilization, including pupillary assessment, as fixed or dilated pupils may indicate possible cerebral herniation requiring urgent intervention. After stabilization, clinicians should obtain a detailed history of anticoagulant or antiplatelet use and underlying coagulation disorders, alongside laboratory evaluation of clotting function and routine blood studies. Identified coagulation abnormalities warrant prompt consultation with hematology and appropriate correction.

Noncontrast CT of the head remains the gold standard for initial diagnosis of ICH due to its wide availability and rapid acquisition.[1] CT can distinguish among various intracranial pathologies, including subarachnoid hemorrhage, ischemic stroke, and ICH. Imaging also reveals hemorrhage size, surrounding edema, mass effect, intraventricular extension, and elevated intracranial pressure. Acute intracerebral hemorrhage appears hyperdense relative to surrounding tissue, with Hounsfield Units ranging from +65 to +95. Over 3 to 4 weeks, the hemorrhage becomes isodense, eventually progressing to hypodensity within 2 to 6 months. Serial MRI can determine hemorrhage acuity by tracking hemoglobin degradation. Oxyhemoglobin appears hypointense on T1 and hyperintense on T2 in the acute phase. Deoxyhemoglobin develops within the first 3 days, appearing iso- to hypointense on T1 and hypointense on T2. Conversion to methemoglobin by 3 to 5 days produces hyperintensity on T1 and hypointensity on T2. Within 7 to 14 days, further degradation to hemosiderin results in hypointensity on both T1- and T2-weighted images. Susceptibility-weighted and gradient-echo sequences enhance the detection of chronic ICH.[15] Acute ICH appears on CT as a hyperdense area within the parenchyma, often surrounded by hypodensity indicating perivascular edema. Clot volume can be approximated by multiplying the maximum depth, height, and length in centimeters and dividing by 2.[10] Clot expansion and rebleeding present major immediate risks, affecting up to 38% of ICH patients.[15] CT with contrast and CT angiography of intracranial vessels can identify underlying vascular pathology. Detection of a vascular abnormality informs surgical planning, as many surgeons prefer elective repair of malformations. A hyperdense signal within the hematoma, known as the “spot sign,” suggests active bleeding, and multiple areas of enhancement indicate increased risk of clot enlargement.[15]

Acute ICH appears on CT as a hyperdense area within the parenchyma, often surrounded by hypodensity indicating perivascular edema. Clot volume can be approximated by multiplying the maximum depth, height, and length in centimeters and dividing by 2.[10] Clot expansion and rebleeding present major immediate risks, affecting up to 38% of ICH patients.[15] CT with contrast and CT angiography of intracranial vessels can identify underlying vascular pathology. Detection of a vascular abnormality informs surgical planning, as many surgeons prefer elective repair of malformations. A hyperdense signal within the hematoma, known as the “spot sign,” suggests active bleeding, and multiple areas of enhancement indicate increased risk of clot enlargement.[15] Vascular lesions causing the ICH are most often suspected in young patients with risk factors. Radiologic indicators include concurrent subarachnoid hemorrhage, calcification within the hematoma (hyperdense on CT), hematoma shape, and its location to major territorial vessels.[15] Aside from CT angiography, vascular abnormalities, eg, arteriovenous malformations and cavernomas, can also be detected on MR angiography and MR venography.[15] Interventional intracranial catheter angiography provides dynamic evaluation of arterial and venous filling and emptying, confirming vascular malformations and guiding clinical management.

Initial Management In the prehospital setting, initial management focuses on airway, breathing, and circulatory support, with the goal of transporting the patient to the nearest emergency department equipped to manage stroke. Obtaining a detailed history from witnesses or family members at the scene can provide critical information regarding trauma, medical history, and substance use.[15] Medical Management Aggressive early medical management in the hospital directly influences morbidity and mortality following ICH. Immediate goals after diagnosis include minimizing the risk of rebleeding and hematoma expansion within the first 24 to 72 hours.[1] Correction of all coagulation abnormalities should occur promptly, including treatment of known factor deficiencies and reversal of anticoagulation, in consultation with hematology. Patients taking vitamin K antagonists require management to achieve an INR below 1.4, using fresh-frozen plasma, vitamin K, or prothrombin complex concentrates.[15] Evidence for recombinant factor VIIa initially looked promising; however, the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial demonstrated reduced hematoma growth but no improvement in survival or functional outcomes.[16] This was subsequently confirmed in the FASTEST trial, which showed similar functional outcomes in patients receiving factor VIIa and those receiving a placebo.[17] Evidence for platelet transfusion in patients on antiplatelet therapy remains under investigation, though small case series suggest reduced final hematoma size when transfusion occurs within 12 hours of ictus.[15]

Aggressive early medical management in the hospital directly influences morbidity and mortality following ICH. Immediate goals after diagnosis include minimizing the risk of rebleeding and hematoma expansion within the first 24 to 72 hours.[1] Correction of all coagulation abnormalities should occur promptly, including treatment of known factor deficiencies and reversal of anticoagulation, in consultation with hematology. Patients taking vitamin K antagonists require management to achieve an INR below 1.4, using fresh-frozen plasma, vitamin K, or prothrombin complex concentrates.[15] Evidence for recombinant factor VIIa initially looked promising; however, the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial demonstrated reduced hematoma growth but no improvement in survival or functional outcomes.[16] This was subsequently confirmed in the FASTEST trial, which showed similar functional outcomes in patients receiving factor VIIa and those receiving a placebo.[17] Evidence for platelet transfusion in patients on antiplatelet therapy remains under investigation, though small case series suggest reduced final hematoma size when transfusion occurs within 12 hours of ictus.[15] Elevated blood pressure commonly accompanies ICH due to pain, stress, preexisting hypertension, and raised ICP. Persistently high systolic blood pressure increases the risk of hematoma expansion, necessitating careful blood pressure management. Treatment should consider the patient’s baseline pressure, as aggressive reduction may compromise cerebral perfusion in chronically hypertensive patients. American stroke guidelines recommend targeting a systolic blood pressure of around 140 mm Hg in patients presenting with 150 to 220 mm Hg and controlled reduction via continuous infusion in those exceeding 220 mm Hg.[15] Rapid lowering of blood pressure has been extensively studied. The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 (INTERACT2) evaluated rapid correction of hypertension with targets of less than 140 mm Hg versus less than 180 mm Hg for systolic blood pressure. Although their results did not reach statistical significance, a trend toward lower death and severe disability was noted with intensive blood pressure lowering.[18] Similarly, the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial showed no difference in mortality or disability when comparing intensive blood pressure control of 110 to 139 mm Hg versus 140 to 179 mm Hg.[19] In a pooled analysis of both trials, achieving a blood pressure reduction and maintaining it between 130 and 150 mm Hg were associated with improved functional outcomes and reduced neurological deterioration.[20]

Elevated blood pressure commonly accompanies ICH due to pain, stress, preexisting hypertension, and raised ICP. Persistently high systolic blood pressure increases the risk of hematoma expansion, necessitating careful blood pressure management. Treatment should consider the patient’s baseline pressure, as aggressive reduction may compromise cerebral perfusion in chronically hypertensive patients. American stroke guidelines recommend targeting a systolic blood pressure of around 140 mm Hg in patients presenting with 150 to 220 mm Hg and controlled reduction via continuous infusion in those exceeding 220 mm Hg.[15] Rapid lowering of blood pressure has been extensively studied. The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 (INTERACT2) evaluated rapid correction of hypertension with targets of less than 140 mm Hg versus less than 180 mm Hg for systolic blood pressure. Although their results did not reach statistical significance, a trend toward lower death and severe disability was noted with intensive blood pressure lowering.[18] Similarly, the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial showed no difference in mortality or disability when comparing intensive blood pressure control of 110 to 139 mm Hg versus 140 to 179 mm Hg.[19] In a pooled analysis of both trials, achieving a blood pressure reduction and maintaining it between 130 and 150 mm Hg were associated with improved functional outcomes and reduced neurological deterioration.[20] Normoglycemia should be maintained while avoiding hypoglycemia, as strict glucose control has shown mixed effects on mortality.[15] Patients presenting with seizures require antiseizure therapy with agents, eg, phenytoin or levetiracetam, although prophylactic seizure medications do not reduce the incidence of post-ICH epilepsy.[15] Prevention of Secondary Injury

Normoglycemia should be maintained while avoiding hypoglycemia, as strict glucose control has shown mixed effects on mortality.[15] Patients presenting with seizures require antiseizure therapy with agents, eg, phenytoin or levetiracetam, although prophylactic seizure medications do not reduce the incidence of post-ICH epilepsy.[15] Prevention of Secondary Injury Preventing secondary brain injury involves maintaining cerebral perfusion pressure above 70 mm Hg. Conservative measures to reduce ICP include elevating the head of the bed to 30 degrees, providing analgesia, preventing straining, hyperventilation, and sedation. In patients with CT evidence of significant mass effect or impending herniation, osmotic agents, eg, mannitol or hypertonic saline, may be administered, though evidence of efficacy remains limited.[10] Intracranial pressure monitoring can guide management in heavily sedated patients or those otherwise unassessable. Urgent complications include intraventricular extension and hydrocephalus, which occur more rapidly in posterior fossa hemorrhages due to proximity to the fourth ventricle. CSF diversion via external ventricular drain, typically in the right lateral ventricle, reduces ICP and prevents herniation.[1] Surgical Interventions Posterior fossa ICH may benefit from surgical clot evacuation in patients with clots exceeding 3 cm causing brainstem compression, decreased consciousness, or hydrocephalus.[21] Patients with higher GCS and smaller hematoma volumes demonstrate improved postsurgical outcomes.[10]

Urgent complications include intraventricular extension and hydrocephalus, which occur more rapidly in posterior fossa hemorrhages due to proximity to the fourth ventricle. CSF diversion via external ventricular drain, typically in the right lateral ventricle, reduces ICP and prevents herniation.[1] Surgical Interventions Posterior fossa ICH may benefit from surgical clot evacuation in patients with clots exceeding 3 cm causing brainstem compression, decreased consciousness, or hydrocephalus.[21] Patients with higher GCS and smaller hematoma volumes demonstrate improved postsurgical outcomes.[10] The International Surgical Trial in Intracerebral Haemorrhage (STICH) trial, examining surgical intervention for supratentorial ICH, randomized over 1,000 patients within 72 hours to surgery or medical management and found no overall significant benefit. However, patients with lobar hemorrhages less than 1 cm from the cortical surface demonstrated a relative 29% benefit with surgery, whereas those with a GCS below 8 had worse outcomes.[22] STICH II further evaluated early surgery versus medical management for lobar clots under 1 cm without IVH, showing no statistically significant difference, although early surgery benefited severely ill patients.[23] These trials highlight ongoing controversy regarding supratentorial ICH surgery, which remains a life-saving option for declining patients.[9] Decompressive craniectomy, with or without clot evacuation, may be considered in select patients with poor response to medical therapy, with systematic reviews demonstrating improved survival despite high morbidity.[24] The SWITCH trial evaluated decompressive craniectomies in patients with deep supratentorial hemorrhages and found a modest benefit in reducing severe disability when compared with medical management alone.[25]

The International Surgical Trial in Intracerebral Haemorrhage (STICH) trial, examining surgical intervention for supratentorial ICH, randomized over 1,000 patients within 72 hours to surgery or medical management and found no overall significant benefit. However, patients with lobar hemorrhages less than 1 cm from the cortical surface demonstrated a relative 29% benefit with surgery, whereas those with a GCS below 8 had worse outcomes.[22] STICH II further evaluated early surgery versus medical management for lobar clots under 1 cm without IVH, showing no statistically significant difference, although early surgery benefited severely ill patients.[23] These trials highlight ongoing controversy regarding supratentorial ICH surgery, which remains a life-saving option for declining patients.[9] Decompressive craniectomy, with or without clot evacuation, may be considered in select patients with poor response to medical therapy, with systematic reviews demonstrating improved survival despite high morbidity.[24] The SWITCH trial evaluated decompressive craniectomies in patients with deep supratentorial hemorrhages and found a modest benefit in reducing severe disability when compared with medical management alone.[25] ICH treatment using minimally invasive techniques is being developed and undertaken worldwide, providing the benefit of less parenchymal brain trauma and reduced surgical time. Current techniques involve stereotactic guidance and catheter insertion to deliver thrombolytic therapy into the clot and, if appropriate, enable aspiration. The MISTIE trial (Minimally Invasive Surgery Plus rtPA [recombinant tissue plasminogen activator] for intracerebral hemorrhage evacuation) has shown that rtPA administered into the clot improves hematoma clearance compared with conservative management.[2] More recently, the ENRICH trial demonstrated lower 30-day mortality in patients undergoing minimally invasive, trans-sulcal parafascicular surgery compared with medical management alone.[26][27] Further, the Clot Lysis Evaluating Accelerated Resolution on Intraventricular Hemorrhage (CLEAR-IVH) trial found that rtPA may improve clearance of the blood load from the ventricles; however, no significant difference was observed in functional outcomes at 180 days.[28]

Many pathologies can present themselves acutely with symptoms and signs similar to those of acute ICH. The common symptoms of headache and nausea, along with clinical manifestations of decreased consciousness, confusion, seizures, and focal neurological deficit, are often seen with other intracranial hemorrhages, eg, a subarachnoid hemorrhage (SAH) and a subdural hemorrhage (both acute and chronic), neoplasms (primary and secondary), and infection. The primary feature of a SAH is the pathognomonic sudden onset, severe headache "like being hit at the back of the head." Apart from this feature, which may not always be expressed so eloquently, patients may present much the same way as those with acute ICH. Please see StatPearls' companion resource, "Subarachnoid Hemorrhage," for further information. In a SAH, an unenhanced CT Head would reveal blood within the subarachnoid space and ventricular cisterns rather than within the parenchyma, as seen in an ICH. An acute subdural hematoma may have similar symptoms. Please see StatPearls' companion resource, "Subdural Hematoma," for further information. However, the key differentiating factor is a history of recent trauma preceding the presentation. Chronic subdural hemorrhages are most commonly seen in older adults, particularly those on blood-thinning medication, and history is often of recurrent falls followed by a longer duration of headaches, confusion, or focal neurological deficit. Both acute and chronic subdural hematomas can be differentiated on plain CT head as a crescentic extra-axial collection: hypodense in the chronic setting and hyperdense in the acute setting. Brain tumors frequently present insidiously. Due to their gradual progression, most patients can compensate until intracranial pressure is high enough to produce symptoms, eg, headache, nausea, vomiting, seizures, and a decreased GCS. On closer examination of the history, there is often evidence of a subtle progressive history, and contrasted CT imaging is often required to make a diagnosis. Patients with neoplastic lesions may present with hemorrhages into a primary or secondary brain tumor in some situations. This can cause diagnostic uncertainty, often requiring delayed MR imaging to make a more accurate diagnosis of underlying pathology.

Brain tumors frequently present insidiously. Due to their gradual progression, most patients can compensate until intracranial pressure is high enough to produce symptoms, eg, headache, nausea, vomiting, seizures, and a decreased GCS. On closer examination of the history, there is often evidence of a subtle progressive history, and contrasted CT imaging is often required to make a diagnosis. Patients with neoplastic lesions may present with hemorrhages into a primary or secondary brain tumor in some situations. This can cause diagnostic uncertainty, often requiring delayed MR imaging to make a more accurate diagnosis of underlying pathology. Lastly, infectious collections, eg, subdural empyema and abscesses, can present similarly to acute ICH; however, patients commonly have a history of recent infections in the nasofacial region (ear, sinuses) or systemic symptoms of pyrexia and rigors. Once again, contrast-enhanced CT and MRI can assist in differentiating the pathology.

Acute ICH can have catastrophic consequences, with mortality closely linked to hematoma size, location, and the patient’s GCS on admission. Thirty-day mortality may reach 50%, with most deaths occurring within 24 hours of onset. Intraventricular extension and hydrocephalus often contribute significantly to early deterioration.[2][10] Patients presenting with a GCS below 9 and hematoma volumes of 60 mL or greater face nearly 90% mortality. Hemorrhages in the posterior fossa and brainstem carry particularly poor prognoses due to the high risk of obstructive hydrocephalus and compromise of vital life-sustaining functions. Less than 20% of survivors regain independence at 6 months post-hemorrhage.[2] Additional factors, including age and comorbidities, further influence outcomes. The ICH score has been validated to predict 30-day mortality based on a 6-point grading scale. The components of the ICH score include GCS at presentation, ICH volume, intraventricular extension, location (supratentorial vs infratentorial), and age. The ICH score demonstrated mortality rates of 13%, 26%, 72%, 97%, and 100% for scores 1 to 5, respectively. No patients scored 6 in the initial report.[29] Although definitive outcome prediction remains elusive, early withdrawal of care can create a self-fulfilling prophecy. Consequently, full medical treatment should be provided to all patients with acute ICH who lack an advance directive or known wishes during the first 24 to 48 hours post-ictus.[9]

Approximately 30% to 50% of patients with ICH experience clot extension into the ventricles, a phenomenon particularly common in thalamic hemorrhages due to the anatomical proximity to the third ventricle and the natural medial flow of blood.[13] Patients with intraventricular hemorrhage (IVH) often demonstrate poorer functional outcomes, likely resulting from periventricular tissue compression and injury, inflammatory responses to blood products within the ventricular system, and obstructive hydrocephalus with its associated complications.[30] Obstructive hydrocephalus, a frequent complication of IVH, can lead to life-threatening increases in ICP. Larger intraventricular blood volumes increase the risk of obstruction. Pacchioni granulations within the arachnoid villi may become partially blocked by blood products, causing communicating hydrocephalus, which contributes to significant morbidity.[13] Seizures occur both as a presenting feature of ICH and as a delayed complication, sometimes developing after 2 hours of hemorrhage. Approximately 70% of seizures occur within 24 hours, and 90% occur within 72 hours of ictus. Early seizures (occurring within 2 hours of the initial hemorrhage) result from neuronal tissue architectural changes and biochemical dysfunction, whereas delayed seizures typically arise from gliosis and tissue scarring.[13] Nonconvulsive seizures, detected on cEEG, may occur in up to 28% of patients within 72 hours and often correlate with sudden GCS decline and hematomas in seizure-prone regions (eg, the temporal lobe or cortical surface). Delayed seizures are frequently associated with increased mass effect and midline shift, suggesting hematoma expansion.[13] Passero et al reported a 5% to 27% risk of delayed recurrent seizures or post-ICH epilepsy.[31] Venous thromboembolism (VTE), including DVT and PE, commonly complicates hospitalization in critically ill patients and occurs in 3% to 7% of ICH cases.[13] Asymptomatic DVTs can occur in up to 17% of patients.[23] Immobility from hemiplegia or hemiparesis, discontinuation of anticoagulant therapy, diagnostic challenges surrounding prophylactic anticoagulation, advanced age, and a prothrombotic state after acute hemorrhage all contribute to VTE development.[13]

Venous thromboembolism (VTE), including DVT and PE, commonly complicates hospitalization in critically ill patients and occurs in 3% to 7% of ICH cases.[13] Asymptomatic DVTs can occur in up to 17% of patients.[23] Immobility from hemiplegia or hemiparesis, discontinuation of anticoagulant therapy, diagnostic challenges surrounding prophylactic anticoagulation, advanced age, and a prothrombotic state after acute hemorrhage all contribute to VTE development.[13] Acute ICH frequently triggers transient hyperglycemia in approximately 60% of patients, lasting up to 72 hours as part of the stress response. Studies demonstrate a positive correlation between hyperglycemia and hematoma size, hematoma expansion, and perihematomal edema, establishing elevated blood glucose as an independent predictor of poorer functional outcomes.[13] During the acute phase of ICH, over 70% of patients present with hypertension (≥140/90 mm Hg), even in the absence of a prior history. This may reflect neuroendocrine upregulation, including sympathetic nervous system activation and renin-angiotensin axis stimulation, as well as increased cardiac output in response to raised ICP.[13] Although elevated blood pressure is associated with hematoma expansion, rebleeding, and poorer outcomes, the relationship between blood pressure and mortality follows a U-shaped distribution, as hypotension also compromises cerebral perfusion, leading to cerebral ischemia and increased risk.[13]

In recent years, the signs and symptoms of stroke have been increasingly publicized using the mnemonic FAST (facial weakness, arm weakness, speech problems, and time to call). Consequently, a larger population can identify the pertinent characteristics when they see these changes in their friends and family. Further promotion regarding the importance of immediate medical attention may help reduce morbidity and mortality from an ICH. Various patient-specific risk factors are reversible if patients are made aware of their significance. Hypertensive patients should be made aware of the importance of keeping their blood pressure controlled. Smokers and those who drink large quantities of alcohol should recognize their increased risk for vascular pathologies. One of the more significant risk factors in recent times is the increased population of patients on anticoagulant and antiplatelet medications. Those on medication that can be checked with regular blood tests, eg, the International Normalized Ratio (INR) for vitamin K antagonist warfarin, should undergo routine testing. Patients and their healthcare team should promptly manage elevated INR to reduce the risk of bleeding. Following an ICH, patients and their families should be informed that the disability seen in those who survive acute ICH can be significant to prepare them for a life of dependence. Patients who undergo open brain surgery or those who have seizures will have regulations on their driving status for different time periods depending on their condition and county of residence.

ICH is a life-threatening neurologic emergency characterized by bleeding into the brain parenchyma, resulting in primary mechanical injury and secondary inflammatory damage. Morbidity and mortality correlate with hematoma size, location, level of consciousness, intraventricular extension, and early expansion. Optimal outcomes depend on rapid recognition, prompt imaging, reversal of coagulopathy, blood pressure control, and prevention of secondary brain injury. Time-sensitive diagnosis using non-contrast CT and early implementation of evidence-based management, including adherence to the American Stroke Association Guidelines for the Management of Spontaneous Intracerebral Hemorrhage, remain central to improving survival and functional recovery.[32] Effective care requires coordinated interprofessional teamwork. Family members and first responders provide essential historical details, including medication use and patient wishes. Paramedics stabilize airway, breathing, and circulation while communicating critical information during handoff. Emergency and stroke physicians lead rapid assessment and diagnostic planning, supported by radiology teams performing urgent imaging. Nurses monitor neurologic status and recognize deterioration, while pharmacists guide anticoagulation reversal and medication safety. Neurologists, neurosurgeons, and intensivists collaborate on medical versus surgical strategies, ensuring shared decision-making with patients and families. Rehabilitation specialists, including physical, occupational, and speech therapists, coordinate recovery planning to maximize independence and long-term outcomes.